Edition:
United Kingdom

Tetraphase Pharmaceuticals Inc (TTPH.OQ)

TTPH.OQ on NASDAQ Stock Exchange Global Select Market

2.45USD
16 Oct 2018
Change (% chg)

$0.17 (+7.46%)
Prev Close
$2.28
Open
$2.28
Day's High
$2.48
Day's Low
$2.27
Volume
152,519
Avg. Vol
193,880
52-wk High
$6.97
52-wk Low
$2.06

Chart for

About

Tetraphase Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral... (more)

Overall

Beta: 2.59
Market Cap(Mil.): $396.17
Shares Outstanding(Mil.): 51.05
Dividend: --
Yield (%): --

Financials

  TTPH.OQ Industry Sector
P/E (TTM): -- 30.95 32.69
EPS (TTM): -2.81 -- --
ROI: -73.69 14.77 14.32
ROE: -73.76 16.27 16.04

FDA approves Tetraphase Pharma's antibiotic

Tetraphase Pharmaceuticals Inc said on Monday U.S. health regulators approved its drug to treat complicated intra-abdominal infections, providing a new option to combat the growing threat from treatment-resistant bacteria.

27 Aug 2018

UPDATE 1-U.S. FDA approves Tetraphase Pharma's antibiotic

Aug 27 Tetraphase Pharmaceuticals Inc said on Monday U.S. health regulators approved its drug to treat complicated intra-abdominal infections, providing a new option to combat the growing threat from treatment-resistant bacteria.

27 Aug 2018

U.S. FDA approves Tetraphase Pharma's antibiotic

Aug 27 The U.S. Food and Drug Administration on Monday approved Tetraphase Pharmaceuticals Inc's antibiotic for complicated intra-abdominal infections, providing a new option to combat the growing problem of treatment-resistant bacteria.

27 Aug 2018

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $136.56 +2.61
Pfizer Inc. (PFE.N) $43.93 +0.81
Merck & Co., Inc. (MRK.N) $71.22 +1.76
AstraZeneca plc (AZN.L) 5,763.00 --

Earnings vs. Estimates